Ranger Investment Management L.P. Acquires Shares of 26,869 Medpace Holdings, Inc. $MEDP

Key Points

• Ranger Investment Management acquired 26,869 Medpace shares worth approximately $14.23 million, joining other institutional investors; institutions and hedge funds collectively own 77.98% of the stock.
• Analysts’ average rating remains “Hold”, with an average price target of $584.18, although individual targets range as high as $665.
• Medpace reported strong quarterly results, with EPS of $4.25 beating estimates and revenue rising 17.2% year over year to $707.33 million. However, insiders sold 122,261 shares worth $71.7 million over the past 90 days.

Ranger Investment Management L.P. acquired a new stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 26,869 shares of the company's stock, valued at approximately $14,230,000. Ranger Investment Management L.P. owned approximately 0.10% of Medpace as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. BOKF NA grew its position in Medpace by 0.8% in the 3rd quarter. BOKF NA now owns 2,542 shares of the company's stock valued at $1,307,000 after purchasing an additional 20 shares during the period. Valeo Financial Advisors LLC raised its holdings in Medpace by 5.0% during the fourth quarter. Valeo Financial Advisors LLC now owns 444 shares of the company's stock worth $249,000 after buying an additional 21 shares during the last quarter. UMB Bank n.a. raised its holdings in Medpace by 5.6% during the fourth quarter. UMB Bank n.a. now owns 450 shares of the company's stock worth $253,000 after buying an additional 24 shares during the last quarter. Schulhoff & Co. Inc. lifted its stake in shares of Medpace by 1.1% in the fourth quarter. Schulhoff & Co. Inc. now owns 2,202 shares of the company's stock valued at $1,237,000 after buying an additional 25 shares in the last quarter. Finally, Balefire LLC lifted its stake in shares of Medpace by 6.1% in the first quarter. Balefire LLC now owns 451 shares of the company's stock valued at $217,000 after buying an additional 26 shares in the last quarter. 77.98% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the stock. Robert W. Baird lifted their price objective on shares of Medpace from $547.00 to $624.00 and gave the company a "neutral" rating in a report on Friday, July 24th. Leerink Partners set a $620.00 price target on shares of Medpace in a research report on Thursday, July 23rd. Mizuho lifted their price target on Medpace from $586.00 to $665.00 and gave the company an "outperform" rating in a research note on Friday, July 24th. Barclays set a $600.00 price target on Medpace in a research note on Thursday, July 23rd. Finally, Truist Financial increased their price objective on Medpace from $462.00 to $609.00 and gave the stock a "hold" rating in a research note on Friday, July 24th. Three investment analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of "Hold" and an average price target of $584.18.

Insiders Place Their Bets

In other Medpace news, Director Cornelius P. Mccarthy III sold 1,140 shares of the stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $605.37, for a total value of $690,121.80. Following the completion of the sale, the director owned 12,275 shares in the company, valued at approximately $7,430,916.75. This trade represents a 8.50% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, VP Susan E. Burwig sold 7,500 shares of Medpace stock in a transaction that occurred on Tuesday, July 28th. The stock was sold at an average price of $600.00, for a total transaction of $4,500,000.00. Following the transaction, the vice president directly owned 62,984 shares in the company, valued at approximately $37,790,400. This represents a 10.64% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 122,261 shares of company stock worth $71,729,129 in the last ninety days. 20.50% of the stock is owned by corporate insiders.

Medpace Price Performance

MEDP opened at $620.75 on Monday. Medpace Holdings, Inc. has a 1 year low of $373.00 and a 1 year high of $677.90. The company has a market capitalization of $17.33 billion, a price-to-earnings ratio of 36.39, a P/E/G ratio of 2.77 and a beta of 1.15. The firm's fifty day moving average price is $550.16 and its two-hundred day moving average price is $492.03.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its earnings results on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, beating the consensus estimate of $3.98 by $0.27. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The company had revenue of $707.33 million during the quarter, compared to the consensus estimate of $689.51 million. During the same quarter in the prior year, the company posted $3.10 earnings per share. The firm's revenue for the quarter was up 17.2% on a year-over-year basis. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, equities analysts anticipate that Medpace Holdings, Inc. will post 17.54 EPS for the current year.

Medpace Profile

Medpace Holdings, Inc NASDAQ: MEDP is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace's core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source